Viking Therapeutics (NASDAQ:VKTX) is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Their portfolio consists of promising candidates aimed at treating conditions such as hypothyroidism, non-alcoholic fatty liver disease, and muscle wasting. Viking Therapeutics is dedicated to advancing these projects through clinical trials, with the ultimate objective of addressing unmet medical needs and improving patient lives. Through their rigorous research and innovative approach, they strive to develop effective treatments that can lead to better health outcomes for individuals affected by these disorders.